1. Lesher, G. Y., Froelich, E. D., Gruet, M. D., et al. (1962). 1,8 naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharmacol. Chem. 5, 1063-1068.

2. Blum, M. D., Graham, D. J., and McCloskey, C. A. (1994). Temafloxacin syndrome: Review of 95 cases. Clin. Infect. Dis. 18, 946-950.

3. Domagala, J. M. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33, 685-706.

4. Crumplin, G. C., and Smith, J. T. (1976). Nalidixic acid and bacterial chromosome replication. Nature (London) 260, 643-645.

5. Gellert, M., Mizuuchi, K., O'Dea, M. H., and Nash, H. A. (1976). DNA gyrase: An enzyme that introduces superhelical turns into DAN. Proc. Natl. Acad. Sci. U.S.A. 73, 3872-3876.

6. Gellert, M., Mizuuchi, K., O'Dea, M. H., et al. (1977). Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. U.S.A. 74, 4772-4776.

7. Wang, J. C. (1985). DNA topoisomerases. Annu. Rev. Biochem. 54, 665-697.

8. Gootz, T. D., and Brighty, K. E. (1996). Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Med. Res. Rev. 16, 433-486.

9. Shen, L. S., Mitscher, L. A., Sharma, P. N., O'Daniel, T., Chu, W. T., and Cooper, C. S. (1989). Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry 28, 3886-3894.

10. Neu, H. C. (1993). Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 45 (Suppl. 3), 54-58.

11. Dalhoff, A., Petersen, U., and Endermann, R. (1996). In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy (Basel) 42, 410-425.

12. Felmingham, D., Robbins, M. J., Ingley, K., et al. (1997). In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39 (Suppl. B), 43-49.

13. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P., and Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41, 101-106.

14. Blondeau, J. M. (1999). A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J. Antimicrob. Chemother. 43 (Suppl. B), 1-11.

15. McCloskey, L., Moore, T., Niconovich, N., Donald, B., Broskey, J., Jakielaszek, C., Tittenhouse, S., and Coleman, K. (2000). The in vitro potency of gemifloxacin against a range of recent clinical isolates from the USA. J. Antimicrob. Chemother. 45 (Suppl. 1), 13-20.

16. Ball, P. (1994). Bacterial resistance to fluoroquinolones: Lessons to be learned. Infection 22 (Suppl. 2), S140-S147.

17. Cruciani, M., and Basseti, D. (1994). The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. J. Antimicrob. Chemother. 33, 403-417.

18. Piddock, L. J. V. (1994). New quinolones and Gram-positive bacteria. Antimicrob. Agents Chemother. 38, 163-169.

19. Edelstein, P. H. (1998). Antimicrobial chemotherapy for legionnaires disease: Time for a change. Ann. Intern. Med. 129, 328-330.

20. Bryan, L. E., Bedard, J., Wong, S., and Chamberland, S. (1989). Quinolone antimicrobial agents: Mechanisms of action and resistance development. Clin. Invest. Med. 12, 14-19.

21. Wolfson, J. S., and Hooper, D. C. (1989). Bacterial resistance to quinolones: Mechanisms and clinical importance. Rev. Infect. Dis. 11 (Suppl. 5), S960-S968.

22. Kaatz, G. W., and Seo, S. M. (1995). Inducible Nor-A mediated multi-drug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39, 2650-2655.

23. Janoir, C., Zeller, V., Kitzis, M. D., Moreua, N. J., and Gutmann, L. (1996). High level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in par C and gyr A. Antimicrob. Agents Chemother. 40, 2760-2764.

24. Courvalin, P. (1990). Plasmid-mediated 4 quinolone resistance: A real or apparent absence. Antimicrob. Agents Chemother. 34, 681-684.

25. Ball, P. (1990). Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: Clinical significance and therapeutic approaches. J. Antimicrob. Chemo-ther. 26 (Suppl. F), 165-179.

26. Thornsberry, C. (1994). Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection 22 (Suppl. 2), S80-S89.

27. Kresken, M., Hafner, D., Mittermayer, H., et al. (1994). Prevalence of fluoroquinolone resistance in Europe. Infection 22 (Suppl. 2), S90-S98.

28. Oteo, J., Aracil, B., Hoyo, J. F., et al. (1999). Do the quinolones still constitute valid empirical therapy for community acquired urinary tract infections in Spain. Clin. Microbiol. Infect. 5, 654-656.

Ball, P. (1994). Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis. Clin. Infect. Dis. 20, 560-563. Muder, R. R., Brennen, C., Goetz, A. M., Wagener, M. M., and Rihs, J. D. (1991). Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among Gram-negative isolates in a Veterans Affairs Medical Center. Antimicrob. Agents Chemother. 35, 256-258. Pena, C., Albareda, J. M., Pallares, R., Pujol, M., Tubau, F. E., and Ariza, J. (1995). Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39, 520-524.

Garau, J., Xercavins, M., Rodriguez-Carballeira, M., etal. (1999). Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob. Agents Chemother. 43, 2736-2741.

Bazile Pham Khac, S., Truong, Q. C., and Lafont, J.-P., et al. (1996). Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Antimicrob. Agents Chemother. 40, 15041507.

Stein, G. E. (1996). Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23 (Suppl. 1), S19-S24.

Gerding, D. N., and Hitt, J. A. (1989). Tissue penetration of the new quinolones in humans. Rev. Infect. Dis. 11 (Suppl. 5), S1046-S1057.

Decre, D., and Bergogne-Berezin, E. (1993). Pharmacokinetics of quinolones with special reference to the respiratory tree. J. Antimicrob. Chemother. 31, 331-343. Wise, R. (1999). A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyqui-nolone, and its potential relation to therapeutic efficacy. Clin. Drug Invest. 17, 365-387. Wise, R., and Honeybourne, D. (1999). Pharmacokinetics and pharmacodynamics of fluoroqui-nolones in the respiratory tract. Eur. Respir. J. 14, 221-229.

Soman, A., Honeybourne, D., Andrews, J., Jevons, G., and Wise, R. (1999). Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400-mg dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44, 835-838.

Fillastre, J. P., Leroy, A., Moulin, B., Dhib, M., Borsa-Lebas, F., and Humbert, G. (1990).

Pharmacokinetics of quinolones in renal insufficiency. J. Antimicrob. Chemother. 26 (Suppl. B),

0 0

Post a comment